摘要
目的:探讨金花清感颗粒治疗新型冠状病毒肺炎的作用机制。方法:根据药物的ADME特性,利用TCMSP平台筛选金花清感颗粒配方的活性化合物与作用靶点,构建化合物靶点网络;基于GeneCards数据库检索新型冠状病毒肺炎相关靶点;采用String数据库、Cytoscape软件构建蛋白质相互作用网络,并将获得的靶点信息利用DAVID数据库分析生物过程及通路富集。结果:经过筛选金花清感颗粒的作用靶点共263个,新型冠状病毒肺炎相关靶点基因共346个,映射后得到共同基因49个。重要基因靶点为IL6、IL1B、CXCL8、CCL2、IL2、IL4、ICAM1、IL10、IFNG、IL1A。GO分析结果显示,富集的关键基因靶点涉及的生物学过程包括细胞因子活性、MAP激酶活性、趋化因子活性、炎症反应、免疫反应等。KEGG通路富集分析显示,金花清感颗粒治疗新型冠状病毒肺炎的信号通路包括TNF信号通路、甲型流感、HIF-1信号通路、NOD样受体信号通路、Toll样受体信号通路、VEGF信号通路、MAPK信号通路、T细胞受体信号传导途径等。结论:金花清感颗粒通过调节免疫、减少炎症的多靶点等多通路机制治疗新型冠状病毒肺炎,但其机制仍需实验证实。
Objective: To explore the mechanism of Jinhua qinggan granules in treating COVID-19.Methods: According to ADME characteristics of drugs, the active ingredients and targets of Jinhua qinggan granules were screened by TCMSP platform, the component target network was constructed;The related targets of COVID-19 were retrieved based on GeneCards database;The protein-protein interaction network was constructed by String database and Cytoscape software.The obtained target information was analyzed using DAVID database to analyze biological processes and pathway enrichment.Results: 263 targets of Jinhua qinggan granules and 346 COVID-19 related target genes were screened out, the mapping resulted in 49 common genes.The important gene targets were IL6,IL1 B,CXCL8,CCL2,IL2,IL4,ICAM1,IL10,IFNG,IL1 A.The GO analysis results showed that the biological processes involved in the enrichment of key gene targets included cytokine activity, MAP kinase activity, chemokine activity, inflammatory response, immune response, etc.KEGG pathway analysis showed that Jinhua qinggan granules′ signaling pathways for the treatment of COVID-19 included TNF signaling pathway, influenza A,HIF-1 signaling pathway, NOD-like receptor signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, MAPK signaling pathway, T cell receptor signaling pathway and so on.Conclusion: Jinhua qinggan granules treats COVID-19 through the multi-targets and multi-pathways of regulating immunity and reducing inflammation, but its mechanism still needs to be confirmed by experiments.
作者
林嘉荣
郑慰武
曾贵兴
林启展
LIN Jia-rong;ZHENG Wei-wu;ZENG Gui-xing;LIN Qi-zhan(The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,China;Second Clinical Medical College,Guangzhou University of Chinese Medicine,Guangzhou 510405,China)
出处
《中药材》
CAS
北大核心
2020年第8期2070-2076,共7页
Journal of Chinese Medicinal Materials
基金
广东省中医院张琪学术经验传承工作室(E43712)